BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12851841)

  • 21. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Importance of urinary interleukin-18 in intravesical immunotherapy with bacillus calmette-guérin for superficial bladder tumors.
    Eto M; Koga H; Noma H; Yamaguchi A; Yoshikai Y; Naito S
    Urol Int; 2005; 75(2):114-8. PubMed ID: 16123563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
    Steinbach F; Schuster F
    Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder.
    Mack D; Höltl W; Bassi P; Brausi M; Ferrari P; de Balincourt C; Sylvester R;
    J Urol; 2001 Feb; 165(2):401-3. PubMed ID: 11176382
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
    Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
    Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW; Chan SF; Chan LW; Chan CK; Ng CF; Cheung HY; Chan SY; Wong WS; Lai FM; To KF; Li ML
    Int J Urol; 2005 May; 12(5):449-55. PubMed ID: 15948743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer.
    Sengiku A; Ito M; Miyazaki Y; Sawazaki H; Takahashi T; Ogura K
    J Urol; 2013 Jul; 190(1):50-4. PubMed ID: 23376145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A; Beyríe Tamayo W; Gozá León F; Muñoz YI
    Arch Esp Urol; 2004; 57(6):606-18. PubMed ID: 15382436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
    Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
    Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intravesical BCG therapy for superficial bladder cancer].
    Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
    Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of superficial bladder cancer.
    Dalbagni G
    Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer].
    Yamada Y; Washida H; Tozawa K; Honma H; Kang K
    Hinyokika Kiyo; 1994 Jul; 40(7):575-9. PubMed ID: 8085517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
    Iida S; Kondo T; Kobayashi H; Hashimoto Y; Goya N; Tanabe K
    Int J Urol; 2009 Mar; 16(3):287-92. PubMed ID: 19207115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.